Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metabolic fingerprint and KADIS-based prediction of exenatide efficacy in suboptimally controlled type 2 diabetes
2008-006251-46Phase 4Completed
- Sponsor
- Institute of Diabetes Gerhardt Katsch
- Start
- Apr 2009
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4 trial of exenatide and insulin glargine in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Institute of Diabetes Gerhardt Katsch. Primary endpoint: KADIS-based prediction accuracy. Started Apr 2009; status: completed.
02
Drugs
exenatideinsulin glargine
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2008-006251-46.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-006251-46.